LTRN
Lantern Pharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.59
−2.61%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.64
From 52W high−85.93%
Volume87028.00
Market cap$8.76M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.64
From 52W high
−85.93%
Volume
87028.00
Market cap
$8.76M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
29.5
MomentumView details →
1D Return
−2.61%
YTD Return
−79.90%
SummaryUpdated Jun 1, 2026
Lantern Pharma Inc. (NASDAQ:LTRN) is a clinical-stage biotechnology company founded in 2013 and headquartered in Dallas, Texas. The company went public in June 2020 and has positioned itself at the intersection of artificial intelligence and cancer drug development. Lantern Pharma focuses on using AI, machine learning, and genomic data to streamline and accelerate the traditionally lengthy and expensive drug development process, with a particular emphasis on precision oncology treatments.
Similar companies
Latest newsMore news →
The lead Taiwan trial site received local Institutional Review Board approval to open Part 2 of Lantern Pharma Inc.'s Phase 2 HARMONIC trial of LP-300.28d agoLantern Pharma Inc. received a NASDAQ notice dated September 25, 2026 that it no longer complies with the $35 million market value of listed securities requirement under Rule 5550(b)(2), with a compliance deadline of March 24, 2027.34d ago